(News release) August 13, 2021
Notice concerning New Mid-Term Management Plan “ASAHI Going Beyond 1000″”

We will aim to proactively further the proliferation of minimally invasive treatment* products from Japan to the world, increasing the quality of life of patients all around the globe while at the same time establishing the Asahi brand globally.

(*) Minimally invasive treatment: Treatment that doesn’t require thoracotomy or laparotomy but rather takes place from blood vessels at the wrists and thighs to minimize the mental and physical damage to clients with small cuts and little pain.

The Group has now established its “ASAHI Going Beyond 1000” new mid-term management plan for the five years from the fiscal year ending June 2022 to the fiscal year ending June 2026.

 

　【Basic Policy】

　　①Develop Grobal Market Strategically and Expand Affected/Treatment Area

　　②Create New Business in Global Niche Market

　　③Develop R&D and Production System Optimized for Global Expansion

　　④Establish Management Foundation for Sustainable Growth

(*) In FYE June 2012, a temporary decrease in sales and profit occurred due to reduced production. The reason for such was that our main factory of our consolidated subsidiary company, Asahi Intecc Thailand was forced to suspend operations temporarily when flooding hit Thailand at that time.

Our group currently provides products to more than 110 countries and regions across the globe. The number of patients with endovascular diseases in which our group’s products are used is expected to continue increasing on a global scale. As such, our group will aim to strengthen its revenue base at a worldwide level by enhancing sales and marketing functions in each region.